GE Healthcare And Takeda Pharmaceutical Co. Ltd. Join Forces To Develop Therapeutic Drugs To Target Liver Diseases

CHALFONT ST. GILES, England & OSAKA, Japan--(BUSINESS WIRE)--GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases. This announcement coincides with AASLD, the 65th Annual Meeting of the American Association for the Study of Liver Diseases, held from 7-11 November in Boston, MA, USA.

Liver disease has almost no visible symptoms, and its progress is characterized by a hardening of the tissues due to fibrosis accompanying the inflammation of the liver and a worsening of symptoms due to cirrhosis. Amid such worldwide trends of recent years as the aging population and less healthy lifestyle habits, non-alcoholic fatty liver disease (NAFLD) has emerged as a type of metabolic syndrome.

Help employers find you! Check out all the jobs and post your resume.